Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Pancreatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 18Urinary Bladder Neoplasms 17Lung Neoplasms 13Ovarian Neoplasms 10Nasopharyngeal Carcinoma 9Neoplasm Metastasis 8Cholangiocarcinoma 8Biliary Tract Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Colorectal Neoplasms 5Recurrence 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasms 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Carcinoma, Transitional Cell 4Osteosarcoma 3Melanoma 3Lymphoma, Non-Hodgkin 3Gallbladder Neoplasms 3Uterine Cervical Neoplasms 2Urologic Neoplasms 2Rectal Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Colonic Neoplasms 2

Interventions

tocilizumab 1siltuximab 1obinutuzumab 1glofitamab 1Oxaliplatin 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × Gemcitabine × 30 days × Clear all
NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡